EP0533834A4 - - Google Patents

Info

Publication number: EP0533834A4
Authority: EP; European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP91912402A

Other languages

English (en)

Other versions

EP0533834A1 (en

Inventor

James C Paulson

Mary S Perez

Federico C A Gaeta

Robert Murray Ratcliffe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cytel Corp

Original Assignee

Cytel Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-15

Filing date

1991-06-14

Publication date

1995-04-19

1991-06-14 Application filed by Cytel Corp filed Critical Cytel Corp

1993-03-31 Publication of EP0533834A1 publication Critical patent/EP0533834A1/en

1995-04-19 Publication of EP0533834A4 publication Critical patent/EP0533834A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Hematology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dispersion Chemistry (AREA)
Wood Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP91912402A 1990-06-15 1991-06-14 Intercellular adhesion mediators Withdrawn EP0533834A1 (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US538853		1983-10-04
US53885390A	1990-06-15	1990-06-15
US61931990A	1990-11-28	1990-11-28
US619319		1990-11-28
US63239090A	1990-12-21	1990-12-21
US632390		1990-12-21
WOPCT/US91/03592		1991-05-22
PCT/US1991/003592 WO1991019501A1 (en)	1990-06-15	1991-05-22	Intercellular adhesion mediators
PCT/US1991/004284 WO1991019502A1 (en)	1990-06-15	1991-06-14	Intercellular adhesion mediators

Publications (2)

Publication Number	Publication Date
EP0533834A1 EP0533834A1 (en)	1993-03-31
EP0533834A4 true EP0533834A4 (fi)	1995-04-19

Family

ID=27415280

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP91912402A Withdrawn EP0533834A1 (en)	1990-06-15	1991-06-14	Intercellular adhesion mediators

Country Status (12)

Country	Link
EP (1)	EP0533834A1 (fi)
AU (2)	AU8007791A (fi)
BR (1)	BR9106556A (fi)
CA (1)	CA2084888A1 (fi)
FI (1)	FI925668L (fi)
HU (1)	HU216312B (fi)
IE (1)	IE912048A1 (fi)
IL (1)	IL98493A (fi)
NO (1)	NO924830L (fi)
NZ (1)	NZ238556A (fi)
SG (1)	SG52563A1 (fi)
WO (2)	WO1991019501A1 (fi)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5753631A (en) *	1990-06-15	1998-05-19	Cytel Corporation	Intercellular adhesion mediators
US5576305A (en) *	1990-06-15	1996-11-19	Cytel Corporation	Intercellular adhesion mediators
US6387884B1 (en)	1990-06-18	2002-05-14	Stanford University	Leukocyte homing modulation
US6391857B1 (en)	1990-06-18	2002-05-21	Stanford University	Methods and compositions for endothelial binding
US5211936A (en) *	1990-07-30	1993-05-18	Glycomed Incorporated	Method of determining a cite of inflammation utilizing elam-1 ligands site
US5648344A (en) *	1990-07-30	1997-07-15	Glycomed Incorporated	Methods of treating inflammation using selection binding compounds
US5211937A (en) *	1990-07-30	1993-05-18	Glycomed Incorporated	Method of determining a site of inflammation utilizing elam-1 ligands
US6124267A (en) *	1991-02-05	2000-09-26	Southpac Trust Internationals, Inc.	O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en)	1991-02-05	2001-10-30	The Board Of Regents Of The University Of Oklahoma	Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5807745A (en) *	1991-03-11	1998-09-15	New England Medical Center Hospitals, Inc.	Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
CA2108786A1 (en) *	1991-04-19	1992-10-20	John L. Magnani	Compositions and methods for endothelial binding
US6121233A (en)	1991-04-19	2000-09-19	John L. Magnani	Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5646123A (en) *	1991-06-10	1997-07-08	Alberta Research Council	Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
JPH07502011A (ja) *	1991-06-10	1995-03-02	グライカムド　インコーポレイテッド	免疫抑制性および寛容原性のオリゴ糖誘導体
GB9114657D0 (en) *	1991-07-06	1991-08-21	Antisoma Ltd	Diagnostic compounds
WO1993005803A1 (en) *	1991-09-25	1993-04-01	Genetics Institute, Inc.	Anti-inflammatory selectin inhibitors
WO1993008802A1 (en) *	1991-10-31	1993-05-13	Fujisawa Pharmaceutical Co., Ltd.	Liposome preparation containing tricyclic compound
GB9208339D0 (en) *	1992-04-15	1992-06-03	Unilever Plc	Treatment composition
US5728802A (en) *	1992-05-06	1998-03-17	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) *	1992-05-06	1997-07-01	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) *	1992-05-06	1997-07-15	Affymax Technologies N.V.	Peptides and compounds that bind to ELAM-1
JPH08504171A (ja) *	1992-05-28	1996-05-07	セントコー・インコーポレーテッド	セレクチン結合のペプチド阻害剤
CA2136844A1 (en) *	1992-05-28	1993-12-09	George A. Heavner	Peptide inhibitors of selectin binding
CA2100412A1 (en) *	1992-07-15	1994-01-16	Yutaka Yamada	Glycolipid derivatives
EP0652775B1 (en) *	1992-07-27	2000-04-19	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Targeting of liposomes to the blood-brain barrier
WO1994005310A1 (en) *	1992-09-08	1994-03-17	Centocor, Inc.	Peptide inhibitors of cellular adhesion
WO1994005314A1 (en) *	1992-09-08	1994-03-17	Centocor, Inc.	Peptide inhibitors of leukocyte adhesion
ES2169724T3 (es) *	1992-10-02	2002-07-16	Alberta Res Council	Propiedades antiinflamatorias, tolerogenicas e inmunoestimulantes de peptidos que enlazan carbohidratos.
US5453272A (en) *	1992-10-02	1995-09-26	Alberta Research Council	Lectin derived carbohydrate binding-peptide
US6406894B1 (en)	1992-12-11	2002-06-18	Glycorex Ab	Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks
EP0601417A3 (de) *	1992-12-11	1998-07-01	Hoechst Aktiengesellschaft	Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO1994014836A1 (en) *	1992-12-18	1994-07-07	Centocor, Inc.	Peptide inhibitors of selectin binding
EP0688327B1 (en) *	1993-03-01	1999-05-06	Glycan Pharmaceuticals, Inc.	Analogs for specific oligosaccharide-protein interactions and uses therefor
WO1994020514A1 (en) *	1993-03-04	1994-09-15	Mect Corporation	Lewis-associated compound, process for producing the same, and anti-inflammatory
US5854218A (en) *	1993-05-14	1998-12-29	Cytel Corporation	Sialyl Lex analogues as inhibitors of cellular adhesion
US5811404A (en) *	1993-05-14	1998-09-22	Cytel Corporation	Sialyl Lex analogues as inhibitors of cellular adhesion
US5976540A (en) *	1993-05-17	1999-11-02	T Cell Sciences, Inc.	Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5856300A (en) *	1994-05-12	1999-01-05	T Cell Sciences, Inc.	Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
ES2174876T3 (es)	1993-05-17	2002-11-16	Avant Immunotherapeutics Inc	Composiciones que comprenden proteinas relacionadas con el complementoy carbohidratos y metodos para producir y usar dichas composiciones.
US5837689A (en) *	1993-06-16	1998-11-17	Glycomed Incorporated	Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) *	1993-06-16	1997-08-19	Glycomed Incorporated	Sialic acid/fucose based medicaments
US5750508A (en) *	1993-06-16	1998-05-12	Glycomed Incorporated	Sialic acid/fucose based medicaments
US5789385A (en) *	1993-06-16	1998-08-04	Glycomed Incorporated	Sialyl Lewisx mimetics containing phenyl backbones
US5679321A (en) *	1993-06-17	1997-10-21	Glycomed Incorporated	Sialic acid/fucose based medicaments
US5559103A (en) *	1993-07-21	1996-09-24	Cytel Corporation	Bivalent sialyl X saccharides
US5783693A (en) *	1993-11-19	1998-07-21	The Regents Of The University Of California	Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995013819A1 (en) *	1993-11-19	1995-05-26	The Regents Of The University Of California	Sulfated ligands for l-selectin and methods of preventing sulfate addition
WO1995014787A1 (en) *	1993-11-22	1995-06-01	Centocor, Inc.	Peptide inhibitors of selecting binding
DE4408248A1 (de) *	1994-03-11	1995-09-14	Hoechst Ag	Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
DE4431280A1 (de)	1994-09-02	1996-03-07	Hoechst Ag	Verfahren zur Isolierung und Reinigung von nukleotidaktivierten Zuckern aus biologischen Quellen
JPH10508580A (ja) *	1994-09-20	1998-08-25	ファルマシア・アンド・アップジョン・カンパニー	Ｅおよびｐセレクチンに対するリガンドのオリゴ糖構造
DE4436164A1 (de) *	1994-10-10	1996-04-11	Hoechst Ag	Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5614615A (en) *	1995-03-21	1997-03-25	The Scripps Research Institute	Sialyl Lewis X mimetics incorporating fucopeptides
US5599915A (en) *	1995-03-21	1997-02-04	The Scripps Research Institute	Sialyl Lewis X mimetics
EP1428832A3 (en) *	1995-08-03	2004-09-22	The Board of Regents for the University of Oklahoma	Peptide and O-glycan inhibitors of selectin mediated inflammation
EP0765884B1 (en) *	1995-08-17	2004-04-14	The Biomembrane Institute	Anti-inflammatory compound
US5876715A (en) *	1995-08-17	1999-03-02	The Biomembrane Institute	Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
AU713078B2 (en) *	1995-09-29	1999-11-25	Glycim Oy	Synthetic multivalent sLEX containing polylactosamines and methods for use
WO1997014707A1 (en) *	1995-10-18	1997-04-24	Cytel Corporation	SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
WO1997018222A2 (en) *	1995-11-13	1997-05-22	Glycomed, Inc.	Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties
EP0902681B1 (en) *	1996-03-01	2002-05-22	The Regents of the University of California	Inhibition of selectin binding
US6033663A (en) *	1996-04-10	2000-03-07	Neose Technologies, Inc.	Nucleic acids encoding GDP-Fucose pyrophosphorylase
US5830871A (en) *	1996-10-28	1998-11-03	The Scripps Research Institute	Inhibitors of E-, P- and L-selectin binding
EP0834572A3 (en) *	1996-10-02	1999-08-25	F. Hoffmann-La Roche Ag	Alpha, gamma-diaminobutyric acid (DAB) containing oligopeptide derivatives
EP1015464A2 (en)	1997-09-05	2000-07-05	Glycim Oy	SYNTHETIC DIVALENT sLex CONTAINING POLYLACTOSAMINES AND METHODS FOR USE
ES2571230T3 (es)	1999-04-09	2016-05-24	Kyowa Hakko Kirin Co Ltd	Procedimiento para controlar la actividad de una molécula inmunofuncional
GB0015923D0 (en) *	2000-06-30	2000-08-23	Astrazeneca Ab	Methods
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7127357B1 (en)	2000-12-08	2006-10-24	The Salk Institute For Biological Studies	Crystal structure of WW domains and methods of use thereof
KR20040015234A (ko)	2001-05-02	2004-02-18	펄듀 리서치 파운데이션	대식세포 매개된 질환의 치료와 진단
WO2002089819A1 (en) *	2001-05-07	2002-11-14	Vereniging Voor Christelijk Wetenschappelijk Onderwijs	Glycoconjugates and uses thereof
US8043602B2 (en)	2002-02-07	2011-10-25	Endocyte, Inc.	Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en)	2002-02-07	2011-10-25	Endocyte, Inc.	Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
EP1534725A2 (en)	2002-05-16	2005-06-01	Glycomimetics, Inc.	Compounds and methods for inhibiting selectin-mediated function
ATE412897T1 (de)	2003-05-30	2008-11-15	Purdue Research Foundation	Diagnoseverfahren für atherosklerose
US20070286896A1 (en) *	2003-08-01	2007-12-13	National Institute Of Advanced Industrial Science And Technology	Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome
US7691810B2 (en)	2003-10-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Method of producing recombinant antithrombin III composition
EP1763533B1 (en)	2003-11-19	2008-01-09	GlycoMimetics, Inc.	Specific antagonist for both e- and p-selectins
EP1904183B1 (en)	2005-07-05	2014-10-15	Purdue Research Foundation	Pharmaceutical composition for the treatment of osteoarthritis
ES2375979T3 (es)	2005-08-09	2012-03-07	Glycomimetics, Inc.	Inhibidores glicomiméticos de la lectina pa-il, lectina pa-iil o ambas lectinas de pseudomonas.
EP2264043B1 (en)	2005-09-02	2017-11-08	GlycoMimetics, Inc.	Heterobifunctional pan-selectin inhibitors
US8795633B2 (en)	2005-09-23	2014-08-05	Purdue Research Foundation	Multiphoton in vivo flow cytometry method and device
CA2668197A1 (en)	2006-11-03	2008-05-15	Philip S. Low	Ex vivo flow cytometry method and device
JP5869205B2 (ja)	2007-02-07	2016-02-24	パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅＲｅｓｅａｒｃｈＦｏｕｎｄａｔｉｏｎ	ポジトロン放射断層画像法
US8961926B2 (en)	2007-05-25	2015-02-24	Purdue Research Foundation	Method of imaging localized infections
WO2009126556A1 (en)	2008-04-08	2009-10-15	Glycomimetics, Inc.	Pan-selectin inhibitor with enhanced pharmacokinetic activity
AU2009338190C1 (en)	2009-01-22	2014-07-17	Momenta Pharmaceuticals, Inc.	Galactose-alpha-1, 3-galactose-containing N-glycans in glycoprotein products derived from CHO cells
WO2012037034A1 (en)	2010-09-14	2012-03-22	Glycomimetics, Inc.	E-selectin antagonists
ES2655443T7 (es)	2011-12-22	2021-03-22	Glycomimetics Inc	Compuestos antagonistas de E-selectina
SI2928476T1 (en)	2012-12-07	2018-06-29	Glycomimetics, Inc.	COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS
CN107108679B (zh)	2014-12-03	2020-10-23	糖模拟物有限公司	E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
CA3009836A1 (en)	2016-01-22	2017-07-27	Glycomimetics, Inc.	Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en)	2016-03-02	2022-04-05	Glycomimetics, Inc	Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja)	2016-08-08	2019-09-05	グリコミメティクス，インコーポレイテッド	Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en)	2016-10-07	2021-07-27	Glycomimetics, Inc.	Highly potent multimeric e-selectin antagonists
JP7272956B2 (ja)	2017-03-15	2023-05-12	グリコミメティクス，インコーポレイテッド	Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
WO2019108750A1 (en)	2017-11-30	2019-06-06	Glycomimetics, Inc.	Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh)	2017-12-29	2020-08-21	糖模拟物有限公司	E-选择蛋白和半乳凝素-3的异双功能抑制剂
CN111867601A (zh)	2018-03-05	2020-10-30	糖模拟物有限公司	用于治疗急性髓系白血病及相关病症的方法
CN110317274A (zh) *	2018-03-30	2019-10-11	积水医疗株式会社	与ncc-st-439抗原特异性反应的单克隆抗体及其制造方法
US11845771B2 (en)	2018-12-27	2023-12-19	Glycomimetics, Inc.	Heterobifunctional inhibitors of E-selectin and galectin-3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0283337A (ja) *	1988-09-18	1990-03-23	Nichirei Corp	癌診断薬及びそれを用いた腫瘍マーカーの回収方法
WO1990013300A1 (en) *	1989-04-28	1990-11-15	Biogen, Inc.	ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)
WO1992007572A1 (en) *	1990-10-25	1992-05-14	Regents Of The University Of Michigan	Agents and methods for binding to elam-1

1991
- 1991-05-22 WO PCT/US1991/003592 patent/WO1991019501A1/en unknown
- 1991-05-22 AU AU80077/91A patent/AU8007791A/en not_active Abandoned
- 1991-06-13 IL IL9849391A patent/IL98493A/en not_active IP Right Cessation
- 1991-06-14 HU HU9204091A patent/HU216312B/hu not_active IP Right Cessation
- 1991-06-14 NZ NZ238556A patent/NZ238556A/en unknown
- 1991-06-14 BR BR919106556A patent/BR9106556A/pt not_active Application Discontinuation
- 1991-06-14 SG SG1996006092A patent/SG52563A1/en unknown
- 1991-06-14 CA CA002084888A patent/CA2084888A1/en not_active Abandoned
- 1991-06-14 IE IE204891A patent/IE912048A1/en unknown
- 1991-06-14 WO PCT/US1991/004284 patent/WO1991019502A1/en not_active Application Discontinuation
- 1991-06-14 AU AU81029/91A patent/AU660931B2/en not_active Ceased
- 1991-06-14 EP EP91912402A patent/EP0533834A1/en not_active Withdrawn
1992
- 1992-12-14 NO NO92924830A patent/NO924830L/no unknown
- 1992-12-14 FI FI925668A patent/FI925668L/fi not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0283337A (ja) *	1988-09-18	1990-03-23	Nichirei Corp	癌診断薬及びそれを用いた腫瘍マーカーの回収方法
WO1990013300A1 (en) *	1989-04-28	1990-11-15	Biogen, Inc.	ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)
WO1992007572A1 (en) *	1990-10-25	1992-05-14	Regents Of The University Of Michigan	Agents and methods for binding to elam-1

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
B.K.BRANDLEY ET AL.: "Carbohydrate Ligands of the LEC Cell Adhesion Molecules", CELL, vol. 63, 30 November 1990 (1990-11-30), pages 861 - 863, XP023908144, DOI: doi:10.1016/0092-8674(90)90487-Y *
C.K.CHING ET AL.: "PURIFICATION AND CHARACTERIZATION OF A PEANUT-AGGLUTININ-BINDING PANCREATIC-CANCER-RELATED SERUM MUCUS GLYCOPROTEIN", J.CANCER, vol. 45, no. 6, 15 June 1990 (1990-06-15), pages 1022 - 1027, XP000605191, DOI: doi:10.1002/ijc.2910450607 *
C.UNDERHILL ET AL.: "THE ROLE OF HYALURONIC ACID IN INTERCELLULAR ADHESION OF CULTERED MOUSE CELLS", EXP.CELL RES., vol. 117, no. 1, 1978, pages 155 - 164, XP024790889, DOI: doi:10.1016/0014-4827(78)90438-X *
D.TYRRELL ET AL.: "Structural requirements for the carbohydrate ligand of E-selectin", PROC.NATL.ACAD.SCI. U.S.A., vol. 88, no. 22, November 1991 (1991-11-01), pages 10372 - 10376, XP000562667, DOI: doi:10.1073/pnas.88.22.10372 *
DATABASE WPI Derwent World Patents Index; AN 90-135674 *
E.L.BERG ET AL.: "A Carbohydrate Domain Common to Both Sialyl Lea and Sialyl Lex Is Recognized by the Endothelial Cell Leukocyte Adhesion Moloecule ELAM-1", J.BIOL.CHEM., vol. 266, no. 23, 15 August 1991 (1991-08-15), pages 14869 - 14872, XP000652121 *
J.B.LOWE ET AL.: "ELAM-1-Dependent Cell Adhesion to Vascular Endothelium Determined by a Transfected Human Fucosyltransferase cDNA", CELL, vol. 63, no. 3, 2 November 1990 (1990-11-02), pages 475 - 484, XP023907995, DOI: doi:10.1016/0092-8674(90)90444-J *
L.J.PICKER ET AL.: "The Neutrophil Selectin LECAM-1 Presents Carbohydrate Ligands to the Vascular Selectins ELAM-1 and GMP-140", CELL, vol. 66, no. 5, 6 September 1991 (1991-09-06), pages 921 - 933, XP023908303, DOI: doi:10.1016/0092-8674(91)90438-5 *
M.L.PHILLIPS ET AL.: "ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sialyl-Lex", SCIENCE, vol. 250, no. 4984, 23 November 1990 (1990-11-23), pages 1130 - 1132, XP000601651, DOI: doi:10.1126/science.1701274 *
M.TIEMEYER ET AL.: "Carbohydrate ligands for endothelial-leukocyte adhesion molecule 1", PROC.NATL.ACAD.SCI. U.S.A., vol. 88, February 1991 (1991-02-01), pages 1138 - 1142, XP000562666, DOI: doi:10.1073/pnas.88.4.1138 *
P.H.JOHNSON ET AL.: "Sialyl compounds as acceptor substrates for the human alpha-3- and alpha-3/4-L-fucosyltransferases", BIOCHEM.SOC.TRANS., vol. 13, no. 6, 1985, pages 1119 - 1120 *
S.D.ROSEN ET AL.: "Lymphocyte attachment to high endothelial venules during recirculation: A possible role for carbohydrates as recognition determinants", MOL.CELL.BIOCHEM., vol. 72, no. 1-2, November 1986 (1986-11-01), pages 153 - 164 *

Also Published As

Publication number	Publication date
HUT69652A (en)	1995-09-28
BR9106556A (pt)	1991-12-26
NO924830L (no)	1993-02-08
WO1991019501A1 (en)	1991-12-26
IE912048A1 (en)	1991-12-18
AU8007791A (en)	1992-01-07
EP0533834A1 (en)	1993-03-31
AU660931B2 (en)	1995-07-13
NZ238556A (en)	1994-01-26
FI925668A0 (fi)	1992-12-14
AU8102991A (en)	1992-01-07
IL98493A (en)	1998-12-06
CA2084888A1 (en)	1991-12-16
WO1991019502A1 (en)	1991-12-26
HU216312B (hu)	1999-06-28
NO924830D0 (no)	1992-12-14
FI925668L (fi)	1992-12-14
SG52563A1 (en)	1998-09-28
HU9204091D0 (en)	1993-11-29

Publication	Publication Date	Title
EP0533834A4 (fi)	1995-04-19
DE4190889T (fi)	1993-02-18
DE4191754T (fi)	1992-10-08
EP0706202A3 (fi)	1996-05-22
FR2666523B1 (fi)	1995-03-03
JPH0496217U (fi)	1992-08-20
DE4190102T (fi)	1992-04-23
DE4191620T (fi)	1993-05-13
CH680892A5 (fi)	1992-12-15
TW216439B (fi)	1993-11-21
DE4092623T1 (fi)	1992-12-10
DE4190581T (fi)	1993-01-28
FR2659259B1 (fi)	1994-08-19
FR2669731B1 (fi)	1993-02-26
EP0467312A3 (fi)	1995-04-05
AU8026491A (fi)	1991-09-19
AU631346B2 (fi)	1992-11-19
ITRM910030A0 (fi)	1991-01-16
DK71290D0 (fi)	1990-03-20
DE4190064T (fi)	1992-12-10
IN173307B (fi)	1994-04-02
IN173768B (fi)	1994-07-09
IN171185B (fi)	1992-08-15
JPH0494040U (fi)	1992-08-14
EP0717178A3 (fi)	1996-07-17

Legal Events

Date	Code	Title	Description
1993-02-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1993-03-31	17P	Request for examination filed	Effective date: 19930113
1993-03-31	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE
1993-04-07	D17D	Deferred search report published (deleted)
1995-04-19	A4	Supplementary search report drawn up and despatched
1995-04-19	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE
2000-07-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2000-09-13	18D	Application deemed to be withdrawn	Effective date: 20000102